Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Glycerin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycerin SCHEMBL28918498 | 0.94 | LMNA (0.56) | LMNAALDH1A1SLC34A1SMN1; SMN2THRB | |
| Glycerin SCHEMBL468638 | 0.94 | LMNA (0.56) | LMNAALDH1A1SLC34A1SMN1; SMN2THRB | |
| Glycerin SCHEMBL6662558 | 0.94 | LMNA (0.56) | LMNAALDH1A1SLC34A1SMN1; SMN2THRB | |
| Glycerin SCHEMBL1792710 | 0.94 | LMNA (0.56) | LMNAALDH1A1SLC34A1SMN1; SMN2THRB | |
| Glycerin SCHEMBL5161896 | 0.94 | LMNA (0.56) | LMNAALDH1A1SLC34A1SMN1; SMN2THRB | |
| Glycerin SCHEMBL468813 | 0.94 | LMNA (0.56) | LMNAALDH1A1SLC34A1SMN1; SMN2THRB | |
| Glycerin SCHEMBL28297573 | 0.94 | LMNA (0.56) | LMNAALDH1A1SLC34A1SMN1; SMN2THRB | |
| Glycerin SCHEMBL1134753 | 0.94 | LMNA (0.56) | LMNAALDH1A1SLC34A1SMN1; SMN2THRB | |
| Glycerin SCHEMBL15463836 | 0.94 | LMNA (0.56) | LMNAALDH1A1SLC34A1SMN1; SMN2THRB | |
| Glycerin SCHEMBL5690684 | 0.94 | LMNA (0.56) | LMNAALDH1A1SLC34A1SMN1; SMN2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180311298-A1 | Composition, and Method of Using the Composition, Effective for Minimizing the Harmful Effects Associated With Individuals Suffering from Alcohol Intoxication | BURN-OFF, LLC | 2018-11-01 | — | — | US | claimed |
| US-9186350-B2 | Composition, and method of using the composition, effective for minimizing the harmful effects associated with individuals suffering from alcohol intoxication | GDB PATENT HOLDINGS, LLC (US) | 2015-11-17 | — | — | US | claimed |
| EP-2574237-A1 | Use of a lipoteichoic acid, mono- or polyglycerophosphate for antibacterial pre-treatment and especially in medical devices | Lunamed AG (CH) | 2013-04-03 | — | — | EP | claimed |
| US-20130078194-A1 | COMPOSITIONS FOR DENTAL TREATMENT COMPRISING LIPOTEICHOIC ACIDS OR PARTS THEREOF LIKE MONO- OR POLYGLYCERPHOSPHATES | LUNAMED AG (CH) | 2013-03-28 | — | — | US | claimed |
| EP-2552427-A1 | COMPOSITIONS FOR DENTAL TREATMENT COMPRISING LIPOTEICHOIC ACIDS OR PARTS THEREOF LIKE MONO- OR POLYGLYCERPHOSPHATES | Lunamed AG (CH) | 2013-02-06 | — | — | EP | claimed |
| WO-2013009997-A1 | COMPOSITION, AND METHOD OF USING THE COMPOSITION, EFFECTIVE FOR MINIMIZING THE HARMFUL EFFECTS ASSOCIATED WITH INDIVIDUALS SUFFERING FROM ALCOHOL INTOXICATION | BURN-OFF, LLC (US) | 2013-01-17 | — | — | WO | claimed |
| US-20130017276-A1 | Composition, and Method of Using the Composition, Effective for Minimizing the Harmful Effects Associated with Individuals Suffering from Alcohol Intoxication | GDB PATENT HOLDINGS, LLC | 2013-01-17 | — | — | US | claimed |
| EP-2380565-A1 | Compositions for dental treatment comprising Lipoteichoic acids or parts thereof like mono- or polyglycerphosphates | Lunamed AG (CH) | 2011-10-26 | — | — | EP | claimed |
| WO-2011120707-A1 | COMPOSITIONS FOR DENTAL TREATMENT COMPRISING LIPOTEICHOIC ACIDS OR PARTS THEREOF LIKE MONO- OR POLYGLYCERPHOSPHATES | LUNAMED AG (CH) | 2011-10-06 | — | — | WO | claimed |
| US-20210244784-A1 | COMPOSITION, AND METHOD OF USING THE COMPOSITION, EFFECTIVE FOR MINIMIZING THE HARMFUL EFFECTS ASSOCIATE WITH INDIVIDUALS SUFFERING FROM ALCOHOL INTOXICATION | GDB PATENT HOLDINGS, LLC (US) | 2021-08-12 | — | — | US | disclosed |
| CN-113164765-A | Thrombin inhibitors, formulations and uses thereof | 维颂国际公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20180311298-A1 | Composition, and Method of Using the Composition, Effective for Minimizing the Harmful Effects Associated With Individuals Suffering from Alcohol Intoxication | BURN-OFF, LLC | 2018-11-01 | — | — | US | disclosed |
| CN-105342994-B | Infusion preparation | 株式会社大塚制药工场 | 2018-08-07 | — | — | CN | disclosed |
| US-10028991-B2 | Composition, and method of using the composition, effective for minimizing the harmful effects associated with individuals suffering from alcohol intoxication | GDB PATENT HOLDINGS, LLC (US) | 2018-07-24 | — | — | US | disclosed |
| US-5346704-A | With a compatibility enhancing ingredient consisting of water soluble organic compound; herbicides, fungicides | CHURCH & DWIGHT CO., INC. (US) | 1994-09-13 | — | — | US | disclosed |
| US-5342630-A | Potassium bicarbonate, fatty acid salt and sorbitol compatibility enhancing ingredient | CHURCH & DWIGHT CO., INC. (US) | 1994-08-30 | — | — | US | disclosed |
| US-5338551-A | Powders of fungicidal particles having alkali metal or ammonium bicarbonates adsorbed on their surfaces | CHURCH & DWIGHT CO., INC. A CORPORATION OF DELAWARE | 1994-08-16 | — | — | US | disclosed |
| WO-1994000983-A1 | POLYFUNCTIONAL AGROCHEMICAL BICARBONATE-CONTAINING COMPOSITIONS | CHURCH & DWIGHT COMPANY, INC. (US) | 1994-01-20 | — | — | WO | disclosed |
| WO-1994000982-A1 | ENVIRONMENTALLY SAFE PESTICIDE COMPOSITIONS | CHURCH & DWIGHT COMPANY, INC. (US) | 1994-01-20 | — | — | WO | disclosed |
| WO-1993022914-A1 | POLYFUNCTIONAL BICARBONATE-CONTAINING AGROCHEMICAL COMPOSITIONS | CHURCH & DWIGHT COMPANY, INC. (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130078194-A1 | COMPOSITIONS FOR DENTAL TREATMENT COMPRISING LIPOTEICHOIC ACIDS OR PARTS THEREOF LIKE MONO- OR POLYGLYCERPHOSPHATES | PGLS, DDOST, PHOSPHO1 | LMNA 1782/4885ALDH1A1 3380/4885SLC34A1 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.